Bionik Laboratories Corp.

Equities

BNKL

US09074A2087

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 08:10:00 2023-11-29 pm EST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Bionik Laboratories Corp. -.--% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bionik Laboratories Corp. Announces Executive Changes CI
Bionik Laboratories Corp. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Bionik Laboratories Corp. Auditor Raises 'Going Concern' Doubt CI
Bionik Laboratories Corp. Expands Its Partnership With Lifepoint Health With the Installation of InMotion® Robotic Devices at Four New Locations CI
Bionik Laboratories Corp. announced that it expects to receive $2 million in funding CI
Bionik Laboratories Corp. announced that it has received $0.25 million in funding CI
Bionik Laboratories Corp. announced that it has received $0.5 million in funding CI
Bionik Laboratories Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q3 Revenue $575.1M MT
Bionik Laboratories Corp. announced that it has received $0.4 million in funding from Gd Holding CI
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q2 Revenue $486.2M MT
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q2 Loss $-0.15 MT
Bionik Laboratories Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Bionik Laboratories Corp. Appoints Richard Russo as Chief Executive Officer CI
Bionik Laboratories Corp. Appoints Richard Russo as President CI
Bionik Laboratories Corp. Appoints Dan Gonsalves as Chief Financial Officer CI
Bionik Laboratories Corp. acquired Florida Rehabilitation Center. CI
Bionik Laboratories Corp. announced that it expects to receive $0.25 million in funding from Gd Holding CI
Bionik Laboratories Corp. Announces Resignation of Gerald Malone as Independent Director as Well as Chairman of Its Compensation Committee and Member of Its Audit Committee CI
Bionik Laboratories Corp. Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Earnings Flash (BNKL) BIONIK LABORATORIES Reports Q1 Revenue $242,829 MT
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q1 Loss $-0.19 MT
Bionik Laboratories Corp. Terminates Employment of Loren was as Chief Commercial Officer CI
Bionik Laboratories Corp. Announces the Sale & Installation of a New InMotion® ARM/HAND Robotic Device to Tampa General Hospital for its Rehabilitation Center CI
Earnings Flash (BNKL) BIONIK LABORATORIES Posts Q4 Revenue $191,262 MT
Chart Bionik Laboratories Corp.
More charts
Bionik Laboratories Corp. is a robotics company, which provides neurological functional recovery solutions to stroke survivors and others with neurological and mobility challenges. It uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and deliver recovery for patients with neurological or mobility impairments. It has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development. Its InMotion ARM, and InMotion ARM/HAND products are robotic therapies for the upper limbs. In addition to these fully developed, clinical rehabilitation solutions, it is also developing InMotion Home, which is an upper extremity product that allows the patient to extend their therapy for as long as needed while rehabilitating at home. Its other products are InMotion Robots and InMotion CONNECT.
More about the company
  1. Stock Market
  2. Equities
  3. BNKL Stock
  4. News Bionik Laboratories Corp.
  5. Earnings Flash (BNKL) BIONIK LABORATORIES Reports Q1 Revenue $242,829
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW